<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02148796</url>
  </required_header>
  <id_info>
    <org_study_id>ORBEX-BV2014/06</org_study_id>
    <nct_id>NCT02148796</nct_id>
  </id_info>
  <brief_title>Oral Bacterial Extract for the Prevention of Wheezing Lower Respiratory Tract Illness</brief_title>
  <acronym>ORBEX</acronym>
  <official_title>Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety and Tolerability of ORal Bacterial EXtract for the Prevention of Wheezing Lower Respiratory Tract Illness (ORBEX)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Arizona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate if Broncho-Vaxom® given to high risk
      infants for 10 days, monthly, for two consecutive years can increase time to occurrence of
      the first episode of wheezing lower respiratory tract illness (WLRI) during a third
      observation year after therapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 36 month parallel arm, double-blind, placebo-controlled trial for the prevention of
      WLRI into the third to fifth year of life (30 to 54 mo inclusive) in young children (6-18
      months old) at increased risk for asthma. The trial will be divided into 2 periods. During
      the initial treatment period (first and second years in the study) participants will receive
      Broncho-Vaxom® (3.5 mg) or placebo for ten days each month for two consecutive years. This
      period will allow the observation of key secondary outcomes while participants are receiving
      therapy. A rolling enrollment strategy will be used anticipating a two year enrollment period
      for the whole study. The second period (third year in the study) will be a one year
      observation of the time to occurrence of the first WLRI episode (primary outcome) while off
      study drug along with the secondary outcomes noted above. During both the treatment and
      observation periods, participants will be managed by study physicians using a rescue
      algorithm applied in the PEAK (Prevention of Early Asthma in Kids) trial commensurate with
      the NAEPP-EPR (National Asthma Education and Prevention Program - Expert Panel Report) III
      guidelines.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 3, 2017</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The time to the occurrence of the first WLRI episode in the third observation year while not receiving study drug</measure>
    <time_frame>25 to 36 months +/- 1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The time to first WLRI during the two treatment years while receiving study drug</measure>
    <time_frame>0 to 24 months +/- 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The annualized rate of WLRI episodes during the two years while receiving study drug</measure>
    <time_frame>0 to 24 months +/- 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The annualized rate of WLRI episodes during the third observation year while not receiving study drug</measure>
    <time_frame>25 to 36 months +/- 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The annualized rate of severe wheezing respiratory tract illness (SWLRI) episodes during the two treatment years while receiving study drug.</measure>
    <time_frame>0 to 24 months +/- 1 month</time_frame>
    <description>SWLRI episodes are defined as cough and wheezing &gt; 24 hours AND any one of the following:
Use of more than 6 albuterol treatments in ≤48 hours.
Unscheduled care visit for acute wheezing in doctor's office, urgent care or emergency department -or- hospitalization for wheezing.
Use of systemic corticosteroid prescribed by a licensed medical provider for a wheezing illness with or without a clinical visit.
The annualized rate of SWLRI episodes during the two years while receiving study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The annualized rate of severe wheezing respiratory tract illness (SWLRI) episodes during the third observation year while not receiving study drug.</measure>
    <time_frame>25 to 36 months +/- 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>0 to 24 months +/- 1 month</time_frame>
    <description>Safety and tolerability of Broncho-Vaxom® while receiving study drug during the two year treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>25 to 36 months +/- 1 month</time_frame>
    <description>Safety and tolerability of Broncho-Vaxom® while receiving study drug during the two year treatment period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1076</enrollment>
  <condition>Asthma</condition>
  <condition>Wheezing</condition>
  <arm_group>
    <arm_group_label>Broncho-Vaxom</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One capsule of Broncho-Vaxom for children contains: 3.5 mg of lyophilized bacterial lysates of Haemophilus influenzae, Streptococcus (pneumonia, pyogenes and sanguinis (viridans)), Klebsiella (pneumoniae and ozaenae), Staphylococcus aureus and Moraxella catarrhalis. The content of the capsule will be mixed with a palatable liquid such as fruit juice.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A placebo capsule will be used that will be indistinguishable from the active study drug.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Broncho-Vaxom</intervention_name>
    <description>Active Ingredient: Lyophilised bacterial extract; Chemical Name: OM-85 BV; Strength: 3.5 mg; Excipients: bacterial extract, propyl gallate, sodium glutamate, mannitol, pregelatinised starch, magnesium stearate; Appearance: Blue and white capsule; Dosage Form: 3.5 mg capsule; Manufacturer: OM Pharma SA, Switzerland; Storage: Store in the original package</description>
    <arm_group_label>Broncho-Vaxom</arm_group_label>
    <other_name>OM-85 BV VEGETAL</other_name>
    <other_name>Broncho-Vaxom concentrate (bacterial lysate)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A placebo capsule will be used that will be indistinguishable from the active study drug.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adequate completion of informed consent process with written documentation. The
             participant's legally acceptable representative must have provided the appropriate
             written informed consent. Assent forms will not be used due to the age of the
             participant population; however, for procedures later in the study when participants
             are older, age appropriate assent will be obtained, if required by local IRB.

          -  Age: 6-18 months of age inclusive at randomization which means 5 to 17 months of age
             inclusive on entry into the one month run-in period. At least half of all enrolled
             children will be between 6 and 12 months of age at randomization.

          -  Participants will meet at least one of the following criteria, which have been
             associated with an increased risk of wheezing respiratory illnesses and asthma: a)
             Parental history of asthma -or- b) Physician-diagnosed atopic dermatitis in the
             participant.

          -  Participants may be either male or female.

          -  Participants will have at least one parent/guardian who can communicate with the study
             staff to allow assessment of study outcomes. All study materials used by
             parent/guardian will be made available in English and in Spanish.

        The child's parent/guardian must have a working direct contact telephone.

        Exclusion Criteria:

          -  Participants may not have had more than two prior WLRI episodes.

          -  Participants may not have had any SWLRI episodes.

          -  Participants may not have a physician's diagnosis of asthma.

          -  Participants may not have a systemic illness (other than allergy) including (but not
             limited to) recurrent seizures, chronic gastroesophageal reflux (GER) requiring
             medical treatment, major congenital anomalies, physical and intellectual delay,
             cerebral palsy, chest surgery, tuberculosis or other chronic infections, primary or
             secondary immunodeficiency, gastrointestinal malformation or disease or cardiac
             disorder (except a hemodynamically insignificant ASD, VSD or benign heart murmur).

          -  Participants may not have been born earlier than 36 weeks of gestation.

          -  Participants may not have received oxygen for more than 5 days in the neonatal period,
             or received mechanical ventilation with the exclusion of ventilation during anesthesia
             for a minor surgical procedure.

          -  Participants may not have significant neurodevelopmental delay.

          -  Participants may not be below the 3rd percentile for weight.

          -  Participants may not have any other chronic lung disease; e.g. chronic lung disease of
             prematurity (CLDP) or cystic fibrosis.

          -  Participants may not have a history of any life-threatening respiratory illness that
             required intubation and mechanical ventilation.

          -  The participant's family may not be expected to relocate out of study area within 3
             years of the initiation of the study.

          -  Participants may not have received inhaled or systemic corticosteroids for respiratory
             related illness ever, or for other conditions in the month prior to randomization.

          -  Participants may not have ever received immunotherapy.

          -  Participants may not have ever received i.v. gammaglobulins or systemic
             immunosuppressants.

          -  Participants may not have received probiotics (Lactobacilli and Bifidobacteria) in
             medicinal form; (i.e. not including food), regularly for more than 4 months in the 6
             to &lt;12 mo age group or 6 months in the 12 to 18 month group prior to enrollment.

          -  Participant has known sensitivity to any of the study products and any of the
             ingredients to be administered.

          -  Participant has previously been randomized in this study. Participants who failed
             run-in and were not randomized may have study participation terminated and then be
             re-enrolled for a second run-in period.

          -  Participant is currently enrolled in or has completed any other investigational device
             or drug study &lt;30 days prior to screening, or is receiving other investigational
             agent(s).

          -  Participant has a significant medical condition(s), anticipated need for major surgery
             during the study, or any other kind of disorder that may be associated with increased
             risk to the participant, or may interfere with study assessments, outcomes, or the
             ability to provide written informed consent or comply with study procedures, in the
             Investigator's opinion.

          -  The one month run-in period will be used to evaluate adherence to study drug
             administration and electronic communication. At randomization the participant must
             continue to meet enrolment criteria and also have demonstrated 80% adherence to the
             placebo during treatment period; i.e. 8 out of 10 days and a75% response rate to
             weekly mobile phone text queries; i.e. 3 out of 4 weekly text queries.

          -  Ongoing infection (of any organ system) at the time of randomization. This includes
             infections that are being adequately treated.

          -  Unable or unlikely to complete study assessments or the study intervention poses undue
             risk to patient in the opinion of the Investigator.

          -  Families will speak English and/or Spanish.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>18 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernando D Martinez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arizona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wayne J Morgan, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Arizona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dave T Mauger, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Penn State University, Data Coordinating Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fernando D Martinez, MD</last_name>
    <phone>520-626-5954</phone>
    <email>fdmartin@email.arizona.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liz Firmage</last_name>
    <phone>520-626-4272</phone>
    <email>beckette@email.arizona.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wayne J Morgan, MD</last_name>
      <phone>520-626-6754</phone>
      <email>wmorgan@arc.ARIZONA.EDU</email>
    </contact>
    <investigator>
      <last_name>Wayne J Morgan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's National Health System</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Teach, MD</last_name>
      <phone>202-476-6215</phone>
    </contact>
    <investigator>
      <last_name>Stephen Teach, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Fitzpatrick, PhD</last_name>
      <phone>404-727-9112</phone>
      <email>amentro@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Anne Fitzpatrick, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital, Harvard University</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wanda Phipatanakul, MD</last_name>
      <phone>617-355-6117</phone>
      <email>wanda.phipatanakul@childrens.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Wanda Phipatanakul, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonard Bacharier, MD</last_name>
      <phone>314-454-2284</phone>
    </contact>
    <investigator>
      <last_name>Leonard Bacharier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meyer Kattan, MD</last_name>
      <phone>212-305-5122</phone>
      <email>mk2833@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Meyer Kattan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792-4108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan J Jackson, MD</last_name>
      <phone>608-263-7686</phone>
      <email>djj@medicine.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Dan J Jackson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ahanchian H, Jones CM, Chen YS, Sly PD. Respiratory viral infections in children with asthma: do they matter and can we prevent them? BMC Pediatr. 2012 Sep 13;12:147. doi: 10.1186/1471-2431-12-147.</citation>
    <PMID>22974166</PMID>
  </reference>
  <reference>
    <citation>Azad MB, Coneys JG, Kozyrskyj AL, Field CJ, Ramsey CD, Becker AB, Friesen C, Abou-Setta AM, Zarychanski R. Probiotic supplementation during pregnancy or infancy for the prevention of asthma and wheeze: systematic review and meta-analysis. BMJ. 2013 Dec 4;347:f6471. doi: 10.1136/bmj.f6471. Review.</citation>
    <PMID>24304677</PMID>
  </reference>
  <reference>
    <citation>Becker A, Watson W, Ferguson A, Dimich-Ward H, Chan-Yeung M. The Canadian asthma primary prevention study: outcomes at 2 years of age. J Allergy Clin Immunol. 2004 Apr;113(4):650-6.</citation>
    <PMID>15100668</PMID>
  </reference>
  <reference>
    <citation>Beydon N, Davis SD, Lombardi E, Allen JL, Arets HG, Aurora P, Bisgaard H, Davis GM, Ducharme FM, Eigen H, Gappa M, Gaultier C, Gustafsson PM, Hall GL, Hantos Z, Healy MJ, Jones MH, Klug B, Lødrup Carlsen KC, McKenzie SA, Marchal F, Mayer OH, Merkus PJ, Morris MG, Oostveen E, Pillow JJ, Seddon PC, Silverman M, Sly PD, Stocks J, Tepper RS, Vilozni D, Wilson NM; American Thoracic Society/European Respiratory Society Working Group on Infant and Young Children Pulmonary Function Testing. An official American Thoracic Society/European Respiratory Society statement: pulmonary function testing in preschool children. Am J Respir Crit Care Med. 2007 Jun 15;175(12):1304-45. Review.</citation>
    <PMID>17545458</PMID>
  </reference>
  <reference>
    <citation>Bisgaard H, Hermansen MN, Buchvald F, Loland L, Halkjaer LB, Bønnelykke K, Brasholt M, Heltberg A, Vissing NH, Thorsen SV, Stage M, Pipper CB. Childhood asthma after bacterial colonization of the airway in neonates. N Engl J Med. 2007 Oct 11;357(15):1487-95.</citation>
    <PMID>17928596</PMID>
  </reference>
  <reference>
    <citation>Bluestone JA, Auchincloss H, Nepom GT, Rotrosen D, St Clair EW, Turka LA. The Immune Tolerance Network at 10 years: tolerance research at the bedside. Nat Rev Immunol. 2010 Nov;10(11):797-803. doi: 10.1038/nri2869. Review.</citation>
    <PMID>20972473</PMID>
  </reference>
  <reference>
    <citation>Bousquet J, Anto J, Auffray C, Akdis M, Cambon-Thomsen A, Keil T, Haahtela T, Lambrecht BN, Postma DS, Sunyer J, Valenta R, Akdis CA, Annesi-Maesano I, Arno A, Bachert C, Ballester F, Basagana X, Baumgartner U, Bindslev-Jensen C, Brunekreef B, Carlsen KH, Chatzi L, Crameri R, Eveno E, Forastiere F, Garcia-Aymerich J, Guerra S, Hammad H, Heinrich J, Hirsch D, Jacquemin B, Kauffmann F, Kerkhof M, Kogevinas M, Koppelman GH, Kowalski ML, Lau S, Lodrup-Carlsen KC, Lopez-Botet M, Lotvall J, Lupinek C, Maier D, Makela MJ, Martinez FD, Mestres J, Momas I, Nawijn MC, Neubauer A, Oddie S, Palkonen S, Pin I, Pison C, Rancé F, Reitamo S, Rial-Sebbag E, Salapatas M, Siroux V, Smagghe D, Torrent M, Toskala E, van Cauwenberge P, van Oosterhout AJ, Varraso R, von Hertzen L, Wickman M, Wijmenga C, Worm M, Wright J, Zuberbier T. MeDALL (Mechanisms of the Development of ALLergy): an integrated approach from phenotypes to systems medicine. Allergy. 2011 May;66(5):596-604. doi: 10.1111/j.1398-9995.2010.02534.x. Epub 2011 Jan 24. Review.</citation>
    <PMID>21261657</PMID>
  </reference>
  <reference>
    <citation>Carroll KN, Gebretsadik T, Griffin MR, Wu P, Dupont WD, Mitchel EF, Enriquez R, Hartert TV. Increasing burden and risk factors for bronchiolitis-related medical visits in infants enrolled in a state health care insurance plan. Pediatrics. 2008 Jul;122(1):58-64. doi: 10.1542/peds.2007-2087.</citation>
    <PMID>18595987</PMID>
  </reference>
  <reference>
    <citation>Castro-Rodríguez JA, Holberg CJ, Wright AL, Martinez FD. A clinical index to define risk of asthma in young children with recurrent wheezing. Am J Respir Crit Care Med. 2000 Oct;162(4 Pt 1):1403-6.</citation>
    <PMID>11029352</PMID>
  </reference>
  <reference>
    <citation>Collet JP, Ducruet T, Kramer MS, Haggerty J, Floret D, Chomel JJ, Durr F. Stimulation of nonspecific immunity to reduce the risk of recurrent infections in children attending day-care centers. The Epicrèche Research Group. Pediatr Infect Dis J. 1993 Aug;12(8):648-52.</citation>
    <PMID>8414777</PMID>
  </reference>
  <reference>
    <citation>Del-Rio-Navarro BE, Espinosa Rosales F, Flenady V, Sienra-Monge JJ. Immunostimulants for preventing respiratory tract infection in children. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD004974. Review.</citation>
    <PMID>17054227</PMID>
  </reference>
  <reference>
    <citation>De Prost Y - Clinical Study Report (BV-2002/1) Multicentric, randomized, double-blind, placebo-controlled study of the efficacy and safety of Broncho-Vaxom® (OM-85 BV) in children suffering from atopic dermatitis. - Clinical Study Report (30 January 2008).</citation>
  </reference>
  <reference>
    <citation>Ege MJ, Mayer M, Normand AC, Genuneit J, Cookson WO, Braun-Fahrländer C, Heederik D, Piarroux R, von Mutius E; GABRIELA Transregio 22 Study Group. Exposure to environmental microorganisms and childhood asthma. N Engl J Med. 2011 Feb 24;364(8):701-9. doi: 10.1056/NEJMoa1007302.</citation>
    <PMID>21345099</PMID>
  </reference>
  <reference>
    <citation>Evans SE, Scott BL, Clement CG, Larson DT, Kontoyiannis D, Lewis RE, Lasala PR, Pawlik J, Peterson JW, Chopra AK, Klimpel G, Bowden G, Höök M, Xu Y, Tuvim MJ, Dickey BF. Stimulated innate resistance of lung epithelium protects mice broadly against bacteria and fungi. Am J Respir Cell Mol Biol. 2010 Jan;42(1):40-50. doi: 10.1165/rcmb.2008-0260OC. Epub 2009 Mar 27.</citation>
    <PMID>19329554</PMID>
  </reference>
  <reference>
    <citation>FDA Center for Drug Evaluation and Research (CDER) - Orally Inhaled and Intranasal Corticosteroids: Evaluation of the Effects on Growth in Children. Guidance for Industry: March 2007.</citation>
  </reference>
  <reference>
    <citation>Fernandes RM, Bialy LM, Vandermeer B, Tjosvold L, Plint AC, Patel H, Johnson DW, Klassen TP, Hartling L. Glucocorticoids for acute viral bronchiolitis in infants and young children. Cochrane Database Syst Rev. 2013 Jun 4;(6):CD004878. doi: 10.1002/14651858.CD004878.pub4. Review.</citation>
    <PMID>23733383</PMID>
  </reference>
  <reference>
    <citation>Gadomski AM, Brower M. Bronchodilators for bronchiolitis. Cochrane Database Syst Rev. 2010 Dec 8;(12):CD001266. doi: 10.1002/14651858.CD001266.pub2. Review. Update in: Cochrane Database Syst Rev. 2014;6:CD001266.</citation>
    <PMID>21154348</PMID>
  </reference>
  <reference>
    <citation>Guilbert TW, Morgan WJ, Krawiec M, Lemanske RF Jr, Sorkness C, Szefler SJ, Larsen G, Spahn JD, Zeiger RS, Heldt G, Strunk RC, Bacharier LB, Bloomberg GR, Chinchilli VM, Boehmer SJ, Mauger EA, Mauger DT, Taussig LM, Martinez FD; Prevention of Early Asthma in Kids Study,Childhood Asthma Research and Education Network. The Prevention of Early Asthma in Kids study: design, rationale and methods for the Childhood Asthma Research and Education network. Control Clin Trials. 2004 Jun;25(3):286-310.</citation>
    <PMID>15157730</PMID>
  </reference>
  <reference>
    <citation>Guilbert TW, Morgan WJ, Zeiger RS, Mauger DT, Boehmer SJ, Szefler SJ, Bacharier LB, Lemanske RF Jr, Strunk RC, Allen DB, Bloomberg GR, Heldt G, Krawiec M, Larsen G, Liu AH, Chinchilli VM, Sorkness CA, Taussig LM, Martinez FD. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med. 2006 May 11;354(19):1985-97.</citation>
    <PMID>16687711</PMID>
  </reference>
  <reference>
    <citation>Halterman JS, Aligne CA, Auinger P, McBride JT, Szilagyi PG. Inadequate therapy for asthma among children in the United States. Pediatrics. 2000 Jan;105(1 Pt 3):272-6.</citation>
    <PMID>10617735</PMID>
  </reference>
  <reference>
    <citation>Holt PG, Sly PD, Martinez FD, Weiss ST, Björkstén B, von Mutius E, Wahn U. Drug development strategies for asthma: in search of a new paradigm. Nat Immunol. 2004 Jul;5(7):695-8.</citation>
    <PMID>15224096</PMID>
  </reference>
  <reference>
    <citation>Jackson DJ. The role of rhinovirus infections in the development of early childhood asthma. Curr Opin Allergy Clin Immunol. 2010 Apr;10(2):133-8. doi: 10.1097/ACI.0b013e3283352f7c. Review.</citation>
    <PMID>19996738</PMID>
  </reference>
  <reference>
    <citation>Jackson DJ, Gangnon RE, Evans MD, Roberg KA, Anderson EL, Pappas TE, Printz MC, Lee WM, Shult PA, Reisdorf E, Carlson-Dakes KT, Salazar LP, DaSilva DF, Tisler CJ, Gern JE, Lemanske RF Jr. Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. Am J Respir Crit Care Med. 2008 Oct 1;178(7):667-72. doi: 10.1164/rccm.200802-309OC. Epub 2008 Jun 19.</citation>
    <PMID>18565953</PMID>
  </reference>
  <reference>
    <citation>Juniper EF, Guyatt GH, Feeny DH, Ferrie PJ, Griffith LE, Townsend M. Measuring quality of life in children with asthma. Qual Life Res. 1996 Feb;5(1):35-46.</citation>
    <PMID>8901365</PMID>
  </reference>
  <reference>
    <citation>Klassen AF, Landgraf JM, Lee SK, Barer M, Raina P, Chan HW, Matthew D, Brabyn D. Health related quality of life in 3 and 4 year old children and their parents: preliminary findings about a new questionnaire. Health Qual Life Outcomes. 2003 Dec 22;1:81.</citation>
    <PMID>14690543</PMID>
  </reference>
  <reference>
    <citation>Kusel MM, de Klerk NH, Kebadze T, Vohma V, Holt PG, Johnston SL, Sly PD. Early-life respiratory viral infections, atopic sensitization, and risk of subsequent development of persistent asthma. J Allergy Clin Immunol. 2007 May;119(5):1105-10. Epub 2007 Mar 13.</citation>
    <PMID>17353039</PMID>
  </reference>
  <reference>
    <citation>Lau S. What is new in the prevention of atopy and asthma? Curr Opin Allergy Clin Immunol. 2013 Apr;13(2):181-6. doi: 10.1097/ACI.0b013e32835eb7b1. Review.</citation>
    <PMID>23400030</PMID>
  </reference>
  <reference>
    <citation>Maier RM, Palmer MW, Andersen GL, Halonen MJ, Josephson KC, Maier RS, Martinez FD, Neilson JW, Stern DA, Vercelli D, Wright AL. Environmental determinants of and impact on childhood asthma by the bacterial community in household dust. Appl Environ Microbiol. 2010 Apr;76(8):2663-7. doi: 10.1128/AEM.01665-09. Epub 2010 Feb 12.</citation>
    <PMID>20154107</PMID>
  </reference>
  <reference>
    <citation>Mansbach JM, Camargo CA Jr. Respiratory viruses in bronchiolitis and their link to recurrent wheezing and asthma. Clin Lab Med. 2009 Dec;29(4):741-55. doi: 10.1016/j.cll.2009.07.011.</citation>
    <PMID>19892232</PMID>
  </reference>
  <reference>
    <citation>Martinez FD. The connection between early life wheezing and subsequent asthma: The viral march. Allergol Immunopathol (Madr). 2009 Sep-Oct;37(5):249-51. doi: 10.1016/j.aller.2009.06.008.</citation>
    <PMID>19875225</PMID>
  </reference>
  <reference>
    <citation>Martinez FD. New insights into the natural history of asthma: primary prevention on the horizon. J Allergy Clin Immunol. 2011 Nov;128(5):939-45. doi: 10.1016/j.jaci.2011.09.020. Review.</citation>
    <PMID>22036094</PMID>
  </reference>
  <reference>
    <citation>McMahon AW, Levenson MS, McEvoy BW, Mosholder AD, Murphy D. Age and risks of FDA-approved long-acting β₂-adrenergic receptor agonists. Pediatrics. 2011 Nov;128(5):e1147-54. doi: 10.1542/peds.2010-1720. Epub 2011 Oct 24. Review.</citation>
    <PMID>22025595</PMID>
  </reference>
  <reference>
    <citation>Mitchell H, Senturia Y, Gergen P, Baker D, Joseph C, McNiff-Mortimer K, Wedner HJ, Crain E, Eggleston P, Evans R 3rd, Kattan M, Kercsmar C, Leickly F, Malveaux F, Smartt E, Weiss K. Design and methods of the National Cooperative Inner-City Asthma Study. Pediatr Pulmonol. 1997 Oct;24(4):237-52.</citation>
    <PMID>9368258</PMID>
  </reference>
  <reference>
    <citation>Morgan WJ, Crain EF, Gruchalla RS, O'Connor GT, Kattan M, Evans R 3rd, Stout J, Malindzak G, Smartt E, Plaut M, Walter M, Vaughn B, Mitchell H; Inner-City Asthma Study Group. Results of a home-based environmental intervention among urban children with asthma. N Engl J Med. 2004 Sep 9;351(11):1068-80.</citation>
    <PMID>15356304</PMID>
  </reference>
  <reference>
    <citation>Navarro RP, Schaecher KL, Rice GK. Asthma management guidelines: updates, advances, and new options. J Manag Care Pharm. 2007 Aug;13(6 Suppl D):S3-11; quiz S12-3.</citation>
    <PMID>17713993</PMID>
  </reference>
  <reference>
    <citation>Navarro S, Cossalter G, Chiavaroli C, Kanda A, Fleury S, Lazzari A, Cazareth J, Sparwasser T, Dombrowicz D, Glaichenhaus N, Julia V. The oral administration of bacterial extracts prevents asthma via the recruitment of regulatory T cells to the airways. Mucosal Immunol. 2011 Jan;4(1):53-65. doi: 10.1038/mi.2010.51. Epub 2010 Sep 1.</citation>
    <PMID>20811345</PMID>
  </reference>
  <reference>
    <citation>NHIS (2011)] National Health Interview Survey Data - Current Asthma Population Estimates. National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention Hyattsville, MD: http://www.cdc.gov/asthma/nhis/2011/data.htm</citation>
  </reference>
  <reference>
    <citation>NHLBI. National Asthma Education and Prevention Program: Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma; NIH Publication Number 08-5846. October 2007.</citation>
  </reference>
  <reference>
    <citation>Parola C, Salogni L, Vaira X, Scutera S, Somma P, Salvi V, Musso T, Tabbia G, Bardessono M, Pasquali C, Mantovani A, Sozzani S, Bosisio D. Selective activation of human dendritic cells by OM-85 through a NF-kB and MAPK dependent pathway. PLoS One. 2013 Dec 30;8(12):e82867. doi: 10.1371/journal.pone.0082867. eCollection 2013.</citation>
    <PMID>24386121</PMID>
  </reference>
  <reference>
    <citation>Principi N - Clinical Study Report (BV-2005/01) Double-Blind, Placebo-Controlled, Randomised Clinical Study of Broncho-Vaxom in Children Suffering from Recurrent Upper Respiratory Tract Infections. - Clinical Study Report (2 October 2012a).</citation>
  </reference>
  <reference>
    <citation>Pasquali C, Salami O, Taneja M, Gollwitzer ES, Trompette A, Pattaroni C, Yadava K, Bauer J, Marsland BJ. Enhanced Mucosal Antibody Production and Protection against Respiratory Infections Following an Orally Administered Bacterial Extract. Front Med (Lausanne). 2014 Oct 30;1:41. doi: 10.3389/fmed.2014.00041. eCollection 2014.</citation>
    <PMID>25593914</PMID>
  </reference>
  <reference>
    <citation>Principi N - Clinical Study Report (EBV09/01) Double-Blind, Placebo-Controlled, Randomised Clinical Study of Broncho-Vaxom® Drops in Children Suffering from Recurrent Respiratory Tract Infections. - Clinical Study Report (23 October 2012b).</citation>
  </reference>
  <reference>
    <citation>Razi CH, Harmancı K, Abacı A, Özdemir O, Hızlı S, Renda R, Keskin F. The immunostimulant OM-85 BV prevents wheezing attacks in preschool children. J Allergy Clin Immunol. 2010 Oct;126(4):763-9. doi: 10.1016/j.jaci.2010.07.038.</citation>
    <PMID>20920766</PMID>
  </reference>
  <reference>
    <citation>Riedler J, Braun-Fahrländer C, Eder W, Schreuer M, Waser M, Maisch S, Carr D, Schierl R, Nowak D, von Mutius E; ALEX Study Team. Exposure to farming in early life and development of asthma and allergy: a cross-sectional survey. Lancet. 2001 Oct 6;358(9288):1129-33.</citation>
    <PMID>11597666</PMID>
  </reference>
  <reference>
    <citation>Schaad UB. OM-85 BV, an immunostimulant in pediatric recurrent respiratory tract infections: a systematic review. World J Pediatr. 2010 Feb;6(1):5-12. doi: 10.1007/s12519-010-0001-x. Epub 2010 Feb 9. Review.</citation>
    <PMID>20143206</PMID>
  </reference>
  <reference>
    <citation>Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med. 2000 May;161(5):1501-7.</citation>
    <PMID>10806145</PMID>
  </reference>
  <reference>
    <citation>Sly PD, Kusel M, Holt PG. Do early-life viral infections cause asthma? J Allergy Clin Immunol. 2010 Jun;125(6):1202-5. doi: 10.1016/j.jaci.2010.01.024. Epub 2010 Mar 20. Review.</citation>
    <PMID>20304476</PMID>
  </reference>
  <reference>
    <citation>Spertini F - Clinical Study Report (BV-2007/03) Efficacy of Broncho-Vaxom® in Allergic Rhinitis: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study. - Clinical Study Report (31 July 2009)</citation>
  </reference>
  <reference>
    <citation>Strickland DH, Holt PG. T regulatory cells in childhood asthma. Trends Immunol. 2011 Sep;32(9):420-7. doi: 10.1016/j.it.2011.06.010. Epub 2011 Jul 27. Review.</citation>
    <PMID>21798806</PMID>
  </reference>
  <reference>
    <citation>Strickland DH, Judd S, Thomas JA, Larcombe AN, Sly PD, Holt PG. Boosting airway T-regulatory cells by gastrointestinal stimulation as a strategy for asthma control. Mucosal Immunol. 2011 Jan;4(1):43-52. doi: 10.1038/mi.2010.43. Epub 2010 Jul 28.</citation>
    <PMID>20668438</PMID>
  </reference>
  <reference>
    <citation>Thorburn K, Harigopal S, Reddy V, Taylor N, van Saene HK. High incidence of pulmonary bacterial co-infection in children with severe respiratory syncytial virus (RSV) bronchiolitis. Thorax. 2006 Jul;61(7):611-5. Epub 2006 Mar 14.</citation>
    <PMID>16537670</PMID>
  </reference>
  <reference>
    <citation>Tuvim MJ, Evans SE, Clement CG, Dickey BF, Gilbert BE. Augmented lung inflammation protects against influenza A pneumonia. PLoS One. 2009;4(1):e4176. doi: 10.1371/journal.pone.0004176. Epub 2009 Jan 12.</citation>
    <PMID>19137067</PMID>
  </reference>
  <reference>
    <citation>von Mutius E, Vercelli D. Farm living: effects on childhood asthma and allergy. Nat Rev Immunol. 2010 Dec;10(12):861-8. doi: 10.1038/nri2871. Epub 2010 Nov 9. Review.</citation>
    <PMID>21060319</PMID>
  </reference>
  <reference>
    <citation>Wildfire JJ, Gergen PJ, Sorkness CA, Mitchell HE, Calatroni A, Kattan M, Szefler SJ, Teach SJ, Bloomberg GR, Wood RA, Liu AH, Pongracic JA, Chmiel JF, Conroy K, Rivera-Sanchez Y, Busse WW, Morgan WJ. Development and validation of the Composite Asthma Severity Index--an outcome measure for use in children and adolescents. J Allergy Clin Immunol. 2012 Mar;129(3):694-701. doi: 10.1016/j.jaci.2011.12.962. Epub 2012 Jan 12.</citation>
    <PMID>22244599</PMID>
  </reference>
  <reference>
    <citation>Yasuda Y, Matsumura Y, Kasahara K, Ouji N, Sugiura S, Mikasa K, Kita E. Microbial exposure early in life regulates airway inflammation in mice after infection with Streptococcus pneumoniae with enhancement of local resistance. Am J Physiol Lung Cell Mol Physiol. 2010 Jan;298(1):L67-78. doi: 10.1152/ajplung.00193.2009. Epub 2009 Sep 25.</citation>
    <PMID>19783640</PMID>
  </reference>
  <reference>
    <citation>Yoo J, Tcheurekdjian H, Lynch SV, Cabana M, Boushey HA. Microbial manipulation of immune function for asthma prevention: inferences from clinical trials. Proc Am Thorac Soc. 2007 Jul;4(3):277-82. Review.</citation>
    <PMID>17607013</PMID>
  </reference>
  <reference>
    <citation>Yunginger JW, Reed CE, O'Connell EJ, Melton LJ 3rd, O'Fallon WM, Silverstein MD. A community-based study of the epidemiology of asthma. Incidence rates, 1964-1983. Am Rev Respir Dis. 1992 Oct;146(4):888-94.</citation>
    <PMID>1416415</PMID>
  </reference>
  <reference>
    <citation>Zeiger RS, Mauger D, Bacharier LB, Guilbert TW, Martinez FD, Lemanske RF Jr, Strunk RC, Covar R, Szefler SJ, Boehmer S, Jackson DJ, Sorkness CA, Gern JE, Kelly HW, Friedman NJ, Mellon MH, Schatz M, Morgan WJ, Chinchilli VM, Raissy HH, Bade E, Malka-Rais J, Beigelman A, Taussig LM; CARE Network of the National Heart, Lung, and Blood Institute. Daily or intermittent budesonide in preschool children with recurrent wheezing. N Engl J Med. 2011 Nov 24;365(21):1990-2001. doi: 10.1056/NEJMoa1104647.</citation>
    <PMID>22111718</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2014</study_first_submitted>
  <study_first_submitted_qc>May 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2014</study_first_posted>
  <last_update_submitted>January 18, 2017</last_update_submitted>
  <last_update_submitted_qc>January 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Wheezing</keyword>
  <keyword>Lower respiratory tract illness</keyword>
  <keyword>Asthma</keyword>
  <keyword>Atopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Sounds</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Broncho-Vaxom</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

